U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812325) titled 'A Safety and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED)' on Jan. 27.
Brief Summary: A randomized, double-masked, controlled, safety and tolerability study of VRDN-003 in participants with thyroid eye disease (TED)
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease (TED)
Intervention:
DRUG: VRDN-003
VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
DRUG: Placebo
All participants will receive the same number of injections to maintain masking. Maskin...